On January 4, 2022 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, reported that Brian M. Culley, Chief Executive Officer will be presenting at the H.C. Wainwright Bioconnect Virtual Conference (Press release, Lineage Cell Therapeutics, JAN 4, 2022, View Source [SID1234598084]). The corporate presentation will be available to investors on demand, starting on January 10, 2022 at 7:00am ET on the Events and Presentations section of Lineage’s website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 4, 2022 Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, reported that Panna Sharma, Chief Executive Officer and President of Lantern Pharma, will be presenting at the H.C. Wainwright BioConnect 2022 Conference being held virtually January 10-13, 2022 (Press release, Lantern Pharma, JAN 4, 2022, View Source [SID1234598083]). The presentation will be conducted as a fireside chat hosted by H.C. Wainwright Senior Biotechnology Analyst and Managing Director, Michael King.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Lantern Pharma’s presentation will be available on-demand to registered attendees via the conference platform beginning Monday, January 10, 2022 at 7:00 AM Eastern Time.

The webcast of the Company’s presentation can be accessed here: journey.ct.events and on the investor relations section of Lantern Pharma’s website at ir.lanternpharma.com as of 7:00 AM Eastern Time on Monday, January 10, 2022.

On January 4, 2022 Labcorp (NYSE: LH), a leading global life sciences company, reported that members of the executive management team will participate in a virtual fireside chat at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 11 at 4:30 p.m. (ET) (Press release, LabCorp, JAN 4, 2022, View Source [SID1234598082]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available via the Company website at www.Labcorp.com and archived for replay.

On January 4, 2022 Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, reported that Richard Paulson, President and Chief Executive Officer of Karyopharm, will present at the 40th Annual J.P. Morgan Healthcare Conference (Press release, Karyopharm, JAN 4, 2022, View Source [SID1234598081]). The conference is being conducted in a virtual format and the presentation will take place on Tuesday, January 11 at 3:45 p.m. ET, followed by a question and answer breakout session at 4:05 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation and breakout session, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company’s website, View Source, and will be available for replay for 30 days following the event. The presentation slides will also be available on the Company’s website following the event.

On January 4, 2022 Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported that company management will participate at the following upcoming investor conferences in January (Press release, Jounce Therapeutics, JAN 4, 2022, View Source [SID1234598080]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright BioConnect Virtual Conference: Presentation will be available for on-demand viewing starting on January 10, 2022 at 7:00 a.m. ET.
40th Annual J.P. Morgan Healthcare Conference: A live presentation will take place on Thursday, January 13, 2022 at 12:00 p.m. ET.
A webcast of each presentation will be available by visiting "Events and Presentations" in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcasts will be archived for 30 days following the presentation.